CD23-Blocking Peptides and Their Role in Arthritis
Author Information
Author(s): Rambert Jérôme, Mamani-Matsuda Maria, Moynet Daniel, Dubus Pierre, Desplat Vanessa, Kauss Tina, Dehais Joël, Schaeverbeke Thierry, Ezzedine Khaled, Malvy Denis, Vincendeau Philippe, Mossalayi M. Djavad
Primary Institution: Université Bordeaux 2, Bordeaux, France
Hypothesis
Can CD23-blocking peptides reduce inflammation in arthritis?
Conclusion
CD23-blocking peptide (p30A) prevents the activation of monocytes/macrophages without cell toxicity.
Supporting Evidence
- CD23-blocking peptide significantly reduced inflammatory cytokine levels in cell supernatants.
- In vivo studies showed that p30A improved clinical scores in a rat model of arthritis.
- p30A inhibited the activation of macrophages from both healthy and arthritic patients.
- Significant reduction of nitric oxide production was observed with p30A treatment.
Takeaway
Scientists found a special peptide that can stop certain immune cells from causing inflammation in arthritis, which might help treat the disease.
Methodology
In vitro studies on human macrophages and in vivo studies in a rat model of arthritis were conducted to assess the effects of CD23-blocking peptides.
Limitations
The study primarily used animal models, and further research is needed to confirm results in humans.
Participant Demographics
Seven patients with rheumatoid arthritis during an arthritic crisis were included.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website